These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31472881)

  • 1. Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting.
    Polonsky TS; Bakris GL
    Heart Fail Clin; 2019 Oct; 15(4):455-461. PubMed ID: 31472881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade.
    Blankstein R; Bakris GL
    Heart Fail Clin; 2008 Oct; 4(4):425-38. PubMed ID: 18760754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
    O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
    Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.
    Volpe M; Santolamazza C; Tocci G
    Curr Cardiol Rep; 2016 Dec; 18(12):127. PubMed ID: 27796865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
    Knight EL; Glynn RJ; McIntyre KM; Mogun H; Avorn J
    Am Heart J; 1999 Nov; 138(5 Pt 1):849-55. PubMed ID: 10539815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Worsening of renal function during 1 year after hospital discharge is a strong and independent predictor of all-cause mortality in acute decompensated heart failure.
    Ueda T; Kawakami R; Sugawara Y; Okada S; Nishida T; Onoue K; Soeda T; Okayama S; Takeda Y; Watanabe M; Kawata H; Uemura S; Saito Y
    J Am Heart Assoc; 2014 Nov; 3(6):e001174. PubMed ID: 25370599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
    Hameedi A; Chadow HL
    Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract]   [Full Text] [Related]  

  • 12. Antihypertensive drugs and the kidney.
    Nadim MK; Dua R; Campese VM
    Curr Cardiol Rep; 2004 Nov; 6(6):403-8. PubMed ID: 15485598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Hyperkalemia and Worsening Renal Function on the Use of Renin Angiotensin Aldosterone System Inhibitors in Chronic Heart Failure With Reduced Ejection Fraction.
    Pitt B; Rossignol P
    Clin Pharmacol Ther; 2017 Sep; 102(3):389-391. PubMed ID: 28707341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
    Sandmann S; Unger T
    Drugs; 2002; 62 Spec No 1():43-52. PubMed ID: 12036388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
    Brodsky S; Gurbanov K; Abassi Z; Hoffman A; Ruffolo RR; Feuerstein GZ; Winaver J
    Hypertension; 1998 Oct; 32(4):746-52. PubMed ID: 9774374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers.
    Sierra C; de la Sierra A
    Curr Opin Nephrol Hypertens; 2005 Sep; 14(5):435-41. PubMed ID: 16046901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease.
    Ram CV; Vergne-Marini P
    Curr Hypertens Rep; 1999 Oct; 1(5):431-5. PubMed ID: 10981102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
    Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
    J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with a calcium channel blocker and an angiotensin blocker in a rat systolic heart failure model with hypertension.
    Namba M; Kim S; Zhan Y; Nakao T; Iwao H
    Hypertens Res; 2002 May; 25(3):461-6. PubMed ID: 12135327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.